BiondVax Pharmaceuticals Ltd.
BVXV · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.05 | -0.01 | -0.01 |
| FCF Yield | -18.44% | -12.20% | 76.12% | 0.00% |
| EV / EBITDA | -13.39 | -12.33 | -2.98 | 8.19 |
| Quality | ||||
| ROIC | -14.10% | -16.49% | 252.46% | 14.14% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.76 | 0.87 | 0.59 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | 1,400,579.94% |
| Free Cash Flow Growth | -6.13% | -119.95% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -6.59 | -4.09 | -0.81 | 3.29 |
| Interest Coverage | 0.00 | -9.68 | 0.00 | 0.63 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |